Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsCephalosporin

    Cephalosporin

    Jump to

    • Lincoln Pharma earmarks around Rs 30 crore for expansion of Cephalosporin products portfolio

      The company has also acquired a facility in Mehsana for this, and expects the commercial operations from the plant to start from March 2022, Lincoln Pharmaceutical said in a regulatory filing.

    • EU bans imports from Ranbaxy's antibiotic injectables unit

      European authorities inspected all units at Ranbaxy's Dewas plant, in Madhya Pradesh, in June and did not approve the manufacturing practices at the unit that makes injectable cephalosporin antibiotics, Ranbaxy said in a stock market filing on Thursday.

    • Aurobindo Pharma jumps as FDA removes Unit VI import ban

      Shares of Aurobindo Pharma surged more than 8 percent on Thursday after it said the US Food and Drug Administration has lifted the import alert for non-sterile products manufactured in its unit VI cephalosporin facility in Hyderabad, Andhra Pradesh.

    • Nectar Lifesciences gets European nod for Punjab plant

      Nectar Lifesciences has received European approval for its Cephalosporin APIs manufacturing facility at Derabassi in Punjab.

    • Orchid Chemicals' Chennai facility clears USFDA inspection

      Orchid Chemicals & Pharmaceuticals today said its Chennai-based facility has cleared the US health regulator's inspection, paving the way for continuous supply of active pharmaceutical ingredients (APIs) to global markets.

    • Nectar Lifesciences eyes Rs 1300cr topline in FY12

      In an interview with CNBC-TV18’s Latha Venkatesh and Gautam Broker, Dinesh Dua, CEO of Nectar Lifesciences spoke about the results and the road ahead.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347